Department of Neurology and Neurotherapeutics, and Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, U.S.A.
Epilepsia. 2014 Jul;55(7):970-8. doi: 10.1111/epi.12650. Epub 2014 May 23.
Focal cortical dysplasias (FCDs) constitute a prevalent cause of intractable epilepsy in children, and is one of the leading conditions requiring epilepsy surgery. Despite recent advances in the cellular and molecular biology of these conditions, the pathogenetic mechanisms of FCDs remain largely unknown. The purpose if this work is to review the molecular underpinnings of FCDs and to highlight potential therapeutic targets. A systematic review of the literature regarding the histologic, molecular, and electrophysiologic aspects of FCDs was conducted. Disruption of the mammalian target of rapamycin (mTOR) signaling comprises a common pathway underlying the structural and electrical disturbances of some FCDs. Other mechanisms such as viral infections, prematurity, head trauma, and brain tumors are also posited. mTOR inhibitors (i.e., rapamycin) have shown positive results on seizure management in animal models and in a small cohort of patients with FCD. Encouraging progress has been achieved on the molecular and electrophysiologic basis of constitutive cells in the dysplastic tissue. Despite the promising results of mTOR inhibitors, large-scale randomized trials are in need to evaluate their efficacy and side effects, along with additional mechanistic studies for the development of novel, molecular-based diagnostic and therapeutic approaches.
局灶性皮质发育不良(FCDs)是儿童难治性癫痫的主要病因之一,也是需要进行癫痫手术的主要疾病之一。尽管这些疾病的细胞和分子生物学方面取得了最近的进展,但 FCD 的发病机制仍知之甚少。本文旨在综述 FCD 的分子基础,并强调潜在的治疗靶点。系统回顾了有关 FCD 的组织学、分子和电生理方面的文献。哺乳动物雷帕霉素靶蛋白(mTOR)信号通路的破坏构成了一些 FCD 的结构和电干扰的共同途径。其他机制,如病毒感染、早产、头部创伤和脑肿瘤,也被认为是发病机制。mTOR 抑制剂(如雷帕霉素)在动物模型和一小部分 FCD 患者中对癫痫管理显示出积极的结果。在发育不良组织中固有细胞的分子和电生理基础上已经取得了令人鼓舞的进展。尽管 mTOR 抑制剂有很有前景的结果,但仍需要进行大规模的随机试验来评估其疗效和副作用,以及开展额外的机制研究,以开发新的基于分子的诊断和治疗方法。